Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16557462 | 0.89 | HPGD (0.70) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL16557575 | 0.88 | POLB (0.81) | MEN1KMT2AHTTPOLBALDH1A1 | |
| SCHEMBL16557426 | 0.86 | MEN1 (0.71) | MEN1KMT2AALDH1A1MAPTTSHR | |
| SCHEMBL16557557 | 0.83 | HPGD (0.74) | MEN1KMT2AHTTPOLBALDH1A1 | |
| SCHEMBL16557559 | 0.82 | HPGD (0.67) | MEN1KMT2AALDH1A1MAPTTSHR | |
| SCHEMBL16557561 | 0.82 | HPGD (0.65) | MEN1KMT2AMAPTTSHRLMNA | |
| SCHEMBL16557467 | 0.81 | MAPT (0.67) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL16557563 | 0.81 | HPGD (0.83) | MEN1KMT2AHTTPOLBALDH1A1 | |
| SCHEMBL15583957 | 0.80 | MEN1 (0.72) | MEN1KMT2AHTTPOLBALDH1A1 | |
| SCHEMBL16560505 | 0.79 | HPGD (0.80) | MEN1KMT2APOLBMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-15 | — | — | US | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | MEN1 4530/4885KMT2A 4177/4885HTT 3876/4885 |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | MEN1 4530/4885KMT2A 4177/4885HTT 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.